ArticleACS omega2026
Design, Synthesis, and Biological Evaluation of Anthraquinone Sulfonamide and Carboxamide Analogs: Cytotoxicity and Preliminary HDAC-Modulating Effects.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anthraquinones are well-recognized anticancer scaffolds, but their systematic optimization within an HDAC-inspired pharmacophore framework remains limited. Since HDAC dysregulation is closely associated with cancer progression, chromatin remodeling, and cell-cycle control, applying this design strategy to anthraquinone scaffolds may provide a useful route toward new anticancer analogs. Herein, a focused series of anthraquinone sulfonamide and carboxamide analogs were designed using an extended cap-connecting unit (CU)-linker-terminal zinc-binding group (ZBG) concept. The anthraquinone core was employed as a cap-like scaffold, sulfonamide or carboxamide was employed as the CU, amino acid-derived fragments were employed as linkers, and methyl ester, carboxylic acid, or hydrazide groups were employed as terminal ZBG-like functionalities. Cytotoxicity screening identified sulfonamide hydrazides as the most active subgroup, with
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.